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After an acute coronary syndrome, patients remain at risk of recurrent ischemic 
events despite the use of antiplatelet therapy. In order to reduce the risk of recurrent 
ischemia in the treatment of patients with acute coronary syndromes,  standard oral 
anticoagulants, such as vitamin K antagonists, have been introduced. These drugs have 
an important role in preventing stroke and systemic embolism in patients with atrial 
fibrillation. Vitamin K antagonists (e.g., warfarin) reduce the risk of recurrent cardio-
vascular events and stroke but increase the risk of bleeding. In addition, the traditional 
anticoagulants have other significant drawbacks. Therefore, modulation of the coagulation 
process represents an important target in the development of new oral anticoagulants 
today.  
The new oral anticoagulants selectively target thrombin (dabigatran etexilate) or 
factor Xa (rivaroxaban, apixaban, edoxaban). Unlike traditional anticoagulants, these 
drugs have rapid onset of action and a relatively wide therapeutic range, do not require 
routine prothrombin time (PT) monitoring and have low potential for food and drug 
interaction.  
Dabigatran etexilate and rivaroxaban have been already approved in many 
countries for the prevention of stroke and systemic embolism in patients with atrial 
fibrillation. The third phase of clinical studies in which rivaroxaban was investigated in 
patients with acute coronary syndrome has been successfully completed. Acta Medica 
Medianae 2013;52(3):42-48. 
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Introduction 
 
During the first year after an acute 
coronary syndrome, patients remain at high risk 
of recurrent ischemic events, despite the use of 
antiplatelet therapy consisting of aspirin and 
clopidogrel (1-3). In order to reduce recurrent 
ischemia in the treatment of high-risk patients 
with acute coronary syndrome, standard oral 
anticoagulants, such as vitamin K antagonists, 
have been introduced (2,3).  
These drugs also have an important role in 
preventing stroke and systemic embolism in 
patients with atrial fibrillation. Atrial fibrillation is 
the most common arrhythmia in the elderly. 
Prevalence of atrial fibrillation increases with age. 
It is present in about 10% of the population older 
than 75 years. Clinical and epidemiological studies 
suggest that atrial fibrillation increases the risk of 
stroke (4,5).  
Clinical studies have shown that the use of 
warfarin, a vitamin K antagonist, reduces the risk 
of myocardial infarction and stroke, but also 
increases the risk of bleeding when applied with 
aspirin or a combination of aspirin and clopidogrel 
(1). 
In addition, it should be noted that despite 
its clinical efficacy, warfarin has other, well-known 
drawbacks, such as variable pharmacokinetics, 
slow onset and offset of action, a narrow thera-
peutic window, numerous food and drug inter-
actions, as well as significant inter- and intra- 
individual variability in dose response (Table 1) 
(6,7). Thus, for example, warfarin doses in the 
same patient can range from 1 to 25 mg/day (8). 
Therefore, regular laboratory monitoring of 
prothrombin time (PT) and dose adjustments are 
required to maintain the International Normalized 
Ratio (INR) in the therapeutic range. However, 
even with monitoring, INR often remains outside 
the target range (9). 
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In the recent years, in attempts to over-
come some of the limitations of standard anti-
coagulants, new oral anticoagulants have been 
developed. Dabigatran etexilate and rivaroxaban 
have been already approved in many countries 
for the prevention of stroke and systemic 
embolism in patients with atrial fibrillation. 
Rivaroxaban has successfully completed the 
phase III clinical trial in patients with acute 
coronary syndrome, while the phase III trial of 
apixaban was terminated prematurely because of 
safety reasons. It has not been decided yet 
whether the third phase of testing dabigatran in 
patients with acute coronary syndrome will be 
performed (1). 
 
Method 
 
In order to collect data on new anti-
coagulant drugs we used several sources of 
information. Most data have been collected by 
searching large databases MEDLINE (http://www. 
ncbi.nlm.nih.gov/pubmed). In databases, during 
the period 2007-2012, the following articles are 
requested: review articles related to new oral 
anticoagulant drugs and clinical studies that were 
carried out, tests related to the effectiveness and 
side effects of new oral anticoagulants in patients 
with atrial fibrillation and acute coronary syn-
dromes (original articles). Each found article has 
been reviewed and further analyzed.  
 
 New oral anticoagulants  
 
 The new oral anticoagulants selectively 
target thrombin (dabigatran etexilate) or factor 
Xa (rivaroxaban, apixaban, edoxaban) (Table I, 
Figure 1) (10-12). Dabigatran etexilate and 
rivaroxaban have been approved in many countries 
for the prevention of venous thromboembolism 
after hip and knee arthroplasty, as well as for the 
prevention of stroke and systemic embolism in 
patients with atrial fibrillation, and so far only 
rivaroxaban is approved for the treatment of 
deep vein thrombosis (1,13-15). Unlike warfarin, 
new oral anticoagulants have a rapid onset of 
action and a relatively large therapeutic range, so 
that these drugs do not require laboratory control 
(16). In addition, the new oral anticoagulants act 
selectively on one specific coagulation factor, and 
rarely interact with food and drug (10). 
 It is well-known that thrombin plays a 
central role in the coagulation process as it not 
only converts fibrinogen to fibrin, but also amplifies 
its own generation by feedback activation of 
coagulation factors V, VIII, XI and XIII and 
activated platelet PAR-1 and PAR-4 receptors 
(PAR - protease activated receptors). Therefore, 
thrombin is an important target for new anti-
coagulants (10,11). Oral direct thrombin inhibitors 
cause direct inhibition of thrombin binding to the 
active site located on the surface of thrombin (11). 
In addition to thrombin, factor Xa is also an 
attractive target for new anticoagulants. Factor 
Xa is positioned at the convergence of the 
extrinsic and intrinsic pathways of coagulation, 
and, when activated, one molecule of factor Xa 
can generate >1000 thrombin molecules (10,11). 
Oral factor Xa inhibitors are small molecules that 
can reversibly bind to the active site of factor Xa 
(10).  
 
Table 1. Features of warfarin, dabigatran etexilate, rivaroxaban and apixaban. 
 
Drug Warfarin Dabigatran etexilate Rivaroxaban Apixaban 
Target 
Vitamin K epoxide 
reductase 
Thrombin Factor Xa Factor Xa 
Prodrug No Yes No No 
Bioavailability > 95% 6-7% 80-100% ~66% 
T(max) 72-96h 1-2h 2-4h 3h 
Half-life 40h 9-13h 7-11h 8-15h 
Routine coagulation 
monitoring 
Yes No No No 
Dosing 
Once daily (INR-
adusted) 
Fixed, once or twice 
daily 
Fixed, once or twice 
daily 
Fixed, twice daily 
Elimination No 80% 
67% renal (half is 
inactive drug), 
33% fecal 
25% renal,  
75% fecal 
Potential drug 
interactions 
CYP2C9, 3A4 and 1A2 
Potent 
p-gp inhibitors 
Potent CYP3A4 and 
p-gp inhibitors 
Potent CYP3A4 
inhibitors 
 
T(max) - peak plasma levels; h- hours; INR - international normalized ratio;  
CYP - Cytochrome P; p-gp transporter  - p-glycoprotein transporter.  
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Figure 1. Targets of new oral anticoagulants: dabigatran etexilate, rivaroxaban, apixaban and edoxaban 
a) Oral direct thrombin inhibitors 
 
Dabigatran etexilate 
 
Dabigatran etexilate is a prodrug of dabi-
gatran, a competitive direct thrombin inhibitor. 
After oral administration, dabigatran etexilate is 
rapidly and completely converted to its active 
form dabigatran by esterases (10,11). Oral 
bioavailability of dabigatran is low, 6-7%, as the 
dabigatran drug capsule contains tartaric acid 
which creates an acidic microenvironment that 
allows absorption of dabigatran, independent of 
gastric pH (11,17). It seems that the tartaric acid 
is responsible for the 6-12% incidence of 
dyspepsia observed in the dabigatran-treated 
patients (18). Peak plasma concentrations are 
achieved 1-2 hours after administration. Dabi-
gatran has a half-life of 9-13 hours, which allows 
once- or twice-daily administration (10,11). Given 
that about 80% of drug is excreted unchanged by 
the kidney, and 20% in the bile after conjugation 
of active metabolites, the use of dabigatran is 
contraindicated in patients with severe renal 
insufficiency and in patients with severe hepatic 
insufficiency, although there is no evidence that 
dabigatran is associated with hepatotoxicity (18). 
Dabigatran has relatively few drug interactions 
because its metabolism is independent of cyto-
chrome P450 (CYP) (11,18). However, dabigatran 
etexilate is a substrate for P-glycoprotein (P-gp) 
membrane transporter that is highly expressed in 
the small intestine, and kidney, and coadmi-
nistration of potent P-gp inhibitors, such as 
amiodarone or verapamil, can increase its 
concentration in plasma. The use of rifampicin, a 
P-gp inducers, which reduces the anticoagulant 
effect of dabigatran should be avoided (8,10,11). 
There is no specific antidote to reverse the 
anticoagulant effect of dabigatran; hemodialysis 
is effective in removing about 60% of the 
dabigatran in the blood over 2-3 hours, and can 
be used to treat dabigatran toxicity (11). 
Following successful phase III clinical studies 
((RE-MODEL (n=2076) and RE-NOVATE (n=3494)) 
in patients undergoing total hip replacement or 
total knee replacement (conditions associated 
with a high rate of venous thromboembolism) 
dabigatran etexilate has been initially approved 
for this clinical indication in Europe, Canada and 
Australia in 2008 (13,14). Studies have shown 
that dabigatran, at doses of 220 or 150 mg once 
daily, effective and safe as enoxaparin was 
applied at a dose of 40 mg daily in the prevention 
of venous thrombosis after orthopedic surgery of 
the lower extremities (19,20). 
Based on the results of the RE-LY trial, 
dabigatran etexilat has been approved in the U.S. 
in October 2010, and in Europe in April 2011, for 
the prevention of stroke and systemic embolism 
in patients with atrial fibrillation (15). This study 
compared dabigatran etexilate (110 and 150 mg 
44 
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twice daily) with warfarin in 18.113 patients with 
atrial fibrillation. The primary efficacy outcomes 
were stroke or systemic embolism; the major 
safety endpoint was major bleeding. The stroke 
or systemic embolism rate was significantly lower 
with dabigatran etexilate at a dose of 150 mg 
twice daily (p<0.001) compared to warfarin, but 
not at a dose of 110 mg twice daily (p=0.34). 
The rate of major bleeding with the 150 mg dose 
was not different from that with warfarin 
(p=0.31), while it was significantly lower with 
110 mg dose compared with warfarin (p=0.003) 
(21). In some countries, both doses of dabi-
gatran etexilate are approved, while in the U.S. 
approved only the higher dose (22). 
The U.S. Food and Drug Administration 
(FDA) continuously evaluates post-marketing 
reports of serious bleeding events in patients 
with atrial fibrillation taking dabigatran etexilate. 
In addition, FDA is working to determine whether 
the reports of bleeding in patients taking 
dabigatran etexilate are occurring more commonly 
than would be expected, based on observations 
in the RE-LY study (23). 
Dabigatran etexilate (50-150 mg twice 
daily) was also studied in the second phase of the 
RE-DEEM studies that involved 1861 patients (on 
dual antiplatelet treatment consists of aspirin and 
clopidogrel) after acute coronary syndrome. The 
primary outcome was the composite of major or 
clinically relevant minor bleeding; secondary 
outcomes were indicators of efficacy such as 
reduction in D-dimer levels. Compared with 
placebo, D-dimer concentrations were reduced in 
all dabigatran dose groups (p<0.001), indicating 
a possible, significant potential of dabigatran in 
reducing cardiovascular events when applied in 
combination with dual antiplatelet therapy. However, 
the results showed that dabigatran etexilate, 
compared with placebo, a dose-dependently 
increases the risk of bleeding (7.8% vs. 2.2%, 
p<0.001), so it is not known whether the third 
phase of the study for this indication will be 
conducted (24).  
 
b) Oral factor Xa inhibitors 
 
Rivaroxaban 
 
Rivaroxaban is a direct, specific factor Xa 
inhibitor that does not require a cofactor. It is 
rapidly absorbed after ingestion and the maximal 
plasma concentrations achieved within 2-4 hours 
(12). Rivaroxaban has a half-life of 7-11 hours 
(10,11). Rivaroxaban is a substrat for P-gp and 
CYP3A4, and concomitant administration of potent 
inhibitors of both P-gp and CYP3A4, such as keto-
conazole or HIV protease inhibitors (eg, ritonavir) 
are contraindicated because they increase plasma 
drug levels. Because of its pharmacokinetic and 
pharmacodynamic properties, rivaroxaban can be 
given at fixed doses to adult patients with no 
requirement for routine coagulation monitoring (12). 
Based on the results of the phase III 
ROCKET-AF trial (n=14264), rivaroxaban was 
approved in the Europe and U.S. in 2011 for the 
prevention of stroke and systemic embolism in 
patients with atrial fibrillation (1). The results of 
ROCKET-AF trial showed that rivaroxaban was 
noninferior to warfarin for the prevention of 
stroke and systemic embolism in patients with 
atrial fibrillation (p<0.001 for noninferiority). In 
addition, it was shown that there was no 
significant difference in the risk of major and 
clinically relevant nonmajor bleeding, between 
two study groups (p=0.44), although there was a 
significant reduction in intracranial (p=0.02) and 
fatal bleeding (p=0.003) in the rivaroxaban 
group (25). 
Rivaroxaban has been approved in Europe 
and Canada for the prevention of venous thrombo-
embolism after hip and knee arthroplasty. This 
was based on the results of phase III RECORD 
program (n>12700) which included four RECORD 
trials (12).  
In addition, rivaroxaban has also been 
approved in Europe only (2011), for the treat-
ment of deep venous thrombosis based on 
EINSTEIN program of trials (EINSTEIN-Acute DVT 
(n=3449) and EINSTEIN-Extension trial (n=1197)) 
(2).  
In all four RECORD trials, rivaroxaban was 
superior to enoxaparin in preventing venous 
thromboembolism, with a similar risk of major 
bleeding (12,26-29). The approved dose of 
rivaroxaban is 10 mg daily, starting 6-8 hours 
post-operatively (8). However, pooled analysis of 
four trials indicated a small increase in bleeding, 
an issue of particular concern to orthopedic 
surgeons that carries a potential need for reope-
rations (30). 
The results of phase III EINSTEIN-Acute 
DVT study showed that rivaroxaban alone (15 mg 
twice daily for 3 weeks, followed by 20 mg once 
daily for 3,6 or 12 months) was noninferior for 
the prevention of recurrent venous thrombosis 
versus standard care (enoxaparin plus vitamin K 
antagonist) (p<0.001 for noninferiority). In addition, 
rivaroxaban did not significantly increase the risk 
of major or clinically relevant nonmajor bleeding 
(p=0.77). The EINSTEIN-Extension study included 
patients with confirmed, symptomatic deep vein 
thrombosis or pulmonary thromboembolism, who 
had been treated for 6-12 months with a rivaro-
xaban or a vitamin K antagonist. This study 
showed that rivaroxaban (20 mg once daily for 
an additional 6 or 12 months) were significantly 
more effective in the prevention of recurrent venous 
thrombosis compared with placebo (p<0.001). 
However, the results showed that rivaroxaban, 
compared with placebo, increases the risk of 
major or clinically relevant bleeding (p<0.001) 
(31). 
It is also important to note that in early 
2012 a supplement of New Drug Application 
(NDA) was submitted to the U.S. FDA for the 
rivaroxaban in combination with standard anti-
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platelet therapy to reduce the risk of (thrombotic) 
cardiovascular events in patients with acute 
coronary syndrome (32). 
The application for the supplemental NDA 
in acute coronary syndrome is based on the 
results of phase III clinical trial ATLAS ACS 2 - 
TIMI 51 (n=15.526) which compared rivaroxaban 
(2.5 and 5 mg twice daily) with placebo in 
patients with acute coronary syndrome who are 
receiving standard antiplatelet therapy (aspirin 
and clopidogrel). The primary efficacy end point 
was a composite of death from cardiovascular 
causes, myocardila infarction, or stroke, while the 
secondary efficacy end point was death from any 
cause, miocardial infarction, or stroke. The primary 
safety end point was major bleeding not related 
to coronary-artery bypass grafting. The results of 
the study showed that 2.5 mg dose of rivaro-
xaban reduces the rates of death from cardio-
vascular causes (p=0.002) and the rates of death 
from any cause (P=0.002). However, rivaroxaban 
(2.5 and 5 mg twice daily) increases the rates of 
major bleeding (p<0.001), without a significant 
increase in fatal bleeding (p=0.66) (33). 
 
Apixaban 
 
Apixaban, as an active drug, is absorbed 
rapidly, and maximal plasma concentration are 
achieved three hours after oral aministration. 
Concomitant treatment with potent inhibitors of 
CYP3A4 is contraindicated (10). 
Apixaban is the first new oral anticoagulant 
studied in patients with acute coronary syn-
drome. Apixaban (5-20 mg daily) was studied in 
the phase of the II clinical trial (APRAISE-2) 
involving 1.715 patients with acute coronary 
syndrome who were receiving standard anti-
platelet therapy, aspirin, or a combination of 
aspirin and clopidogrel. The primary outcome was 
major or clinically relevant nonmajor bleeding. A 
secondary outcome was cardiovascular death, 
myocardial infarction, severe recurrent ischemia, 
or ischemic stroke. By the recommendation of 
the Data Monitoring Committee, the 2 higher-
dose (10 mg twice daily and 20 mg once daily) of 
apixaban were discontinued early because of 
excess total bleeding. 
The results of this trial showed  that apixaban 
(2.5 mg twice daily and 10 mg daily) dose-
dependently increased the major or clinically 
relevant nonmajor bleeding (p=0.09 and p=0.005) 
and reduced, though not significantly, ischemic 
events compared with placebo (7.6% and 2.5% 
compared with 8.7% placebo) (34).  
Based on the results of phase II APPRAISE-
2 trial, the phase III of the same trial has been 
carried. APPRAISE-2 (n=7392) enrolled patients 
who were at high risk for recurrent ischemic 
events following acute coronary syndrome and on 
standard antiplatelet therapy. The trial randomized 
patients to either placebo or two 5-mg daily 
doses of apixaban. Unfortunately, phase III clinical 
trial was terminated prematurely because of 
increased risk of major bleeding (p<0.001), 
without a significant reduction in recurrent 
ischemic events (p=0.51) (35). 
Apixaban at a dose of 5 mg twice daily was 
compared to aspirin (81-324 mg daily) for stroke 
prevention in atrial fibrillation (AVERROES trial). 
This study included 5.599 patients who were 
deemed unsuitable for warfarin; it was stopped 
early because of a clear benefit in favour of 
apixaban. The primary efficacy outcome was the 
occurence of stroke or systemic embolism. The 
primary safety outcome was the occurence of 
major beedeing. In this study, apixaban significantly 
reduced the risk of stroke or systemic embolism 
(p<0.001), without a significant increase in the 
risk of major or intracranial bleeding (p=0.66) (36). 
In addition to rivaroxaban and apixaban,  
edoxaban should be also mentioned, which is 
currently being applied in phase III clinical trials 
for the prevention of stroke. The scope of this 
study is to compare the effects of edoxaban (30 
and 60 mg once daily) with warfarin in 16.500 
patients with atrial fibrillation (11 ).  
 
Conclusion 
 
The standard anticoagulant therapy, although 
effective, has significant disadvantages, so it is 
necessary to introduce new oral anticoagulants in 
therapy of patients with atrial fibrillation and 
acute coronary syndrome. For the present, 
dabigatran etexilate and rivaroxaban have gained 
approval for the prevention of stroke and systemic 
embolism in patients with atrial fibrillation, while 
rivaroxaban has successfully completed a phase 
III clinical trial in patients with acute coronary 
syndrome. However, the new anticoagulants 
could not completely replace the standard anti-
coagulant treatment until the results of the study 
demonstrate a satisfactory relation-ship between 
the efficacy and safety of these drugs, as well as 
the economic feasibility of their application.) 
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NOVI ORALNI ANTIKOAGULANTNI LEKOVI KOD ATRIJALNE 
FIBRILACIJE I AKUTNOG KORONARNOG SINDROMA 
 
Aleksandra Novaković, Tatjana Divac, Ivan Stojanović, Predrag Milojević, 
Dragoslav Nenezić 
 
 
Nakon akutnog koronarnog sindroma, kod bolesnika postoji povećan rizik od 
rekurentnih ishemičnih događaja, uprkos primeni antiagregacione terapije. U cilju 
smanjenja rizika od rekurentne ishemije, u terapiju visokorizičnih bolesnika sa akutnim 
koronarnim sindromom uvode se standardni oralni antikoagulansi, kao što su antagonisti 
vitamina K. Ovi lekovi imaju važnu ulogu u prevenciji moždanog udara i sistemskog 
embolizma kod bolesnika sa atrijalnom fibrilacijom. Antagonisti vitamina K (varfarin) 
smanjuju rizik od nastanka ponovnih kardiovaskularnih događaja i moždanog udara, ali  
povećavaju rizik od krvarenja. Pored toga, antagonisti vitamina K poseduju i druge, 
značajne nedostatke, tako da modulacija procesa koagulacije danas predstavlja značajnu 
metu za razvoj novih oralnih antikoagulanasa.  
Novi oralni antikoagulansi deluju selektivno na trombin (dabigatran eteksilat) ili na 
faktor koagulacije Xa (rivaroksaban, apiksaban, edoksaban). Za razliku od standardnih 
antikoagulanasa, imaju brz početak dejstva i relativno veliku terapijsku širinu, ne zahtevaju 
laboratorijsku kontrolu protrombinskog vremena (PT) i retko stupaju u interakcije sa 
hranom i lekovima.  
Dabigatran eteksilat i rivaroksaban su već registrovani u mnogim zemljama za 
prevenciju moždanog udara i sistemskog embolizma kod bolesnika sa atrijalnom 
fibrilacijom. Treća faza kliničke studije u okviru koje je ispitivan rivaroksaban kod bolesnika 
sa akutnim koronarnim sindromom uspešno je završena. Acta Medica Medianae 2013; 
52(3):42-48. 
 
Ključne reči: novi oralni antikoagulansi, akutni koronarni sindrom, atrijalna fibrilacija, 
trombin, faktor Xa 
 
 
